A Study of Single-Agent Eribulin Mesylate as First-Line Therapy for Locally Recurrent or Metastatic Human Epidermal Growth Factor Receptor Two (HER2) Negative Breast Cancer

Clinical trial NCT01268150 · COMPLETED

Trial details

NCT number: NCT01268150
Sponsor: Eisai Inc.
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Locally Recurrent Metastatic Breast Cancer ( HER2 Negative)

Start date: 2011-02-01
Primary completion: 2012-03-01
Enrollment: 56

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.